Osteo-Pharma and Emultech announce joint venture
Osteo-Pharma and Emultech announce joint venture to develop First-In-Class disease modifying treatment for Osteoarthritis
AMSTERDAM, November 17, 2021 (Newswire.com) – Emultech and Osteo-Pharma today announced a joint venture to develop what could be the first disease-modifying treatment for osteoarthritis of the knee. The joint venture, to be called Bone-Tech, brings together Osteo-Pharma’s novel combination drug therapy for the local treatment of osteoarthritis with Emultech’s world leading microfluidics’ microspheres technology. Bone-Tech’s patented OsteoActivator™ microspheres treatment promises to be the first and only extended-release treatment targeting subchondral bone remodelling for patients suffering from osteoarthritis-related pain and disability.
Osteoarthritis (OA), the most common form of arthritis, is a chronic, degenerative disease affecting over 1.5 billion people globally. OA causes life-long pain and is a leading cause of disability in the US and worldwide, accounting for >$185 billion in annual costs in the US alone in 2016. In OA patients, subchondral bone is characterized by impaired bone remodelling and the presence of bone marrow lesions (BML). BML’s are a hallmark in OA diagnosis and are strongly associated with pain, are a prognostic marker for cartilage loss and are predictive for the need for knee replacement surgery.
“Intraosseous injection of OsteoActivator™ microspheres directly into subchondral bone, locally targets osteoblast and osteoclast cells to restore bone remodelling, improves bone quality and relieves pain. There are currently no disease modifying treatments in the OA therapies market and as such OsteoActivator™ microspheres will be the first of its kind” said Jan Gossen, CEO of Osteo-Pharma.
“With its extended-release microsphere formulation, we believe the Bone-Tech product holds the potential to disrupt the current treatment paradigm, and we are dedicated to bringing this important new therapy to market for the millions of patients confronting this relentless disease” said Rene Hansen, CEO of Emultech.
Bone-Tech’s novel approach has demonstrated proof-of-concept in in-vitro and animal studies and is under development in preparation for IND filing and first-in-man studies. The Bone-Tech product employs proprietary microsphere technology for the extended-release of a combination of two well-known therapeutic agents delivered via intraosseous injection. Bone-Tech plans to pursue a rapid and low risk 505(b)(2) strategy to progress the product through clinical trials.
Bone-Tech is actively seeking venture and/or strategic partners to support clinical development. If interested, please contact Bone-Tech using the contact information below.
Osteo-Pharma is a Life Sciences company developing novel medical devices and pharmaceuticals to improve the local healing of bone defects and fractures. Its proprietary OsteoActivator platform is currently used to develop products for both dental and orthopedic applications. The company has recently announced its MREC approval for the initiation of a clinical trial for their lead product, OsteoActivator-P, in patients.
Emultech has developed the first and only continuous production of microparticles based on microfluidics. Emultech’s system enables superior control of particle properties (monodispersity, size, circularity and morphology) with high encapsulation efficiency, resulting in improved and adjustable loading, controlled drug release and degradation profiles with easier injectability. Our process is low energy and safe for all molecules, and parallelization enables instant, low risk, scale-up for high throughput production that is suitable for GMP.
Osteo-Pharma: Jan Gossen, CEO – email@example.com
Emultech: Scott Fleming CCO – firstname.lastname@example.org / Mobile: +31 6 46 87 69 89